Proto Labs COO sells shares, exercises options
Proto Labs Inc Chief Operations Officer Michael R. Kenison reported an exercise-and-sell transaction in company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Proto Labs Inc Chief Operations Officer Michael R. Kenison reported an exercise-and-sell transaction in company stock. On May 7, 2026, he sold 200 shares of Common Stock at $70.00 per share in an open-market sale and exercised stock options to acquire 200 shares at strike prices of $33.52 and $33.84 per share.
The filing shows these trades were made under a pre-arranged 10b5-1 trading plan adopted on August 15, 2025. Following the transactions, he holds 27,186 Common Stock shares directly and continues to hold employee stock options, including grants with remaining balances of 7,455 and 7,612 options that vest annually starting on specified February 13 vesting dates.
Insights
Routine option exercises paired with a small pre-planned sale.
Chief Operations Officer Michael R. Kenison exercised employee stock options for 200 Proto Labs shares at strike prices of $33.52 and $33.84, then sold 200 shares at $70.00 on May 7, 2026. This pattern reflects a classic exercise-and-sell event.
A key detail is the footnote stating the trades occurred under a 10b5-1 plan adopted on August 15, 2025, indicating they were pre-scheduled rather than opportunistic. After these transactions, he still directly owns 27,186 shares and retains option positions of 7,455 and 7,612 options tied to awards that vest in annual February 13 installments, suggesting ongoing long-term equity exposure.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 100 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) | 100 | $0.00 | $0.00 |
| Exercise | Common Stock | 100 | $33.84 | $3K |
| Exercise | Common Stock | 100 | $33.52 | $3K |
| Sale | Common Stock | 200 | $70.00 | $14K |
Footnotes (3)
- F1. These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025.
- F2. 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested.
- F3. 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested.
Key Figures
Key Terms
10b5-1 plan financial
Employee Stock Option financial
open-market sale financial
Exercise or conversion of derivative security financial
vest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Proto Labs (PRLB) COO Michael R. Kenison do in this Form 4 filing?
Were the Proto Labs (PRLB) insider trades made under a Rule 10b5-1 plan?
What stock option activity did the Proto Labs (PRLB) COO report?
What employee stock option balances remain for the Proto Labs (PRLB) COO?
AI-generated analysis. How Rhea-AI works. Not financial advice.